Extended HPV typing as an efficient alternative within HPV ‐based screening programs
Authors:
- Joacim Meneses‐LeónJMJoacim Meneses‐León
- Berenice Rivera‐ParedezBRBerenice Rivera‐Paredez
- Sonia Hernández‐SalazarSHSonia Hernández‐Salazar
- Leticia Torres‐IbarraLTLeticia Torres‐Ibarra
- Martha CarnallaMCMartha Carnalla
- Leith León‐MaldonadoLLLeith León‐Maldonado
- Rubí Hernández‐LópezRHRubí Hernández‐López
- José Damián Cadena‐FiscalJCJosé Damián Cadena‐Fiscal
- Anna B. MoscickiAMAnna B. Moscicki
- Manuel Quiterio‐TrenadoMQManuel Quiterio‐Trenado
- Eduardo Lazcano‐PonceELEduardo Lazcano‐Ponce
- Jorge SalmerónJSJorge Salmerón
Open Access
- 28 March 2026
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 159 (3) , 638-644
Abstract
Extended high‐risk human papilloma virus (hrHPV) typing emerges as a potential alternative for detecting cervical intraepithelial neoplasia 3 (CIN3), without additional triage tests. We evaluate the extended hrHPV typing as an alternative to improve CIN3 detection within an HPV‐based screening program. Between January 2017 and August 2018, 5856 women aged 25–65 years were screened as part of a public cervical cancer screening program of the Tlalpan Sanitary Jurisdiction in Mexico City. HPV testing was performed by BD Onclarity™, which individually detects hrHPV types 16, 18, 31, 45, 51, and 52, and pools of types 33/58, 56/59/66, and 35/39/68. Specific hrHPV types within these pools were further identified using the Atila AmpFire platform. All HPV‐positive women ( n = 691) were referred to colposcopy evaluation for diagnostic confirmation. Of these, 561 women completed both colposcopy and histological confirmation, representing our analytical sample. HPV‐16 alone had a sensitivity of 43.0% and specificity of 85.4% for CIN3 detection. Sequentially adding HPV‐18/33/31/39 increased sensitivity to 100% for CIN3 detection, although with lower specificity (54.5%). The proportion of HPV‐16/18/33/31/39 positive women was 47.0%, with a CIN3 PPV 5.3%. Extended genotyping with HPV‐16/18/33/31/39 achieved 100% sensitivity for CIN3 detection, but a moderate specificity. This strategy aligns with the international recommendation for colposcopy referral in women with a PPV of CIN3 larger than 4.0%.Keywords
Funding Information
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (FOSISS 2013 202468)
This publication has 36 references indexed in Scilit:
- Cervical cancer screening: Impact of collection technique on human papillomavirus detection and genotypingPreventive Medicine Reports, 2025
- Field experience with the 8‐HPV‐type oncoprotein test for cervical cancer screening among HPV‐positive women living with and without HIV in LMICsInternational Journal of Cancer, 2024
- Cross comparison of AmpFire HPV genotyping assay and Roche human papillomavirus (HPV) linear array for HPV genotyping of anal swab samplesJournal of Virological Methods, 2021
- A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programseClinicalMedicine, 2020
- Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki‐67 dual‐stained cytology—Retrospective insights from ATHENAInternational Journal of Cancer, 2019
- Human papillomavirus types in cervical high‐grade lesions or cancer among Nordic women—Potential for preventionCancer Medicine, 2019
- Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV typesInternational Journal of Cancer, 2018
- Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of ChinaJournal of Medical Virology, 2017
- Need for expanded HPV genotyping for cervical screeningPapillomavirus Research, 2016
- Risk assessment to guide the prevention of cervical cancerAmerican Journal of Obstetrics and Gynecology, 2007